Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer

Marcello Riggi, Pierre Ruffie, Sabine Voisin, Isabelle Monnet, Hubert de Cremoux, Jean Claude Saltiel, Michel Martin, Laurence Vergne, Jocelyne Huet, Esteban Cvitkovic

Open source

DOI
10.1016/0277-5379(91)90089-v
Published
1991-10
Container
European Journal of Cancer and Clinical Oncology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/0277-5379-91-90089-v,
  title = {Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer},
  author = {Marcello Riggi and Pierre Ruffie and Sabine Voisin and Isabelle Monnet and Hubert de Cremoux and Jean Claude Saltiel and Michel Martin and Laurence Vergne and Jocelyne Huet and Esteban Cvitkovic},
  year = {1991},
  journal = {European Journal of Cancer and Clinical Oncology},
  doi = {10.1016/0277-5379(91)90089-v},
  url = {https://doi.org/10.1016/0277-5379(91)90089-v}
}

RIS

TY  - JOUR
TI  - Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer
AU  - Marcello Riggi
AU  - Pierre Ruffie
AU  - Sabine Voisin
AU  - Isabelle Monnet
AU  - Hubert de Cremoux
AU  - Jean Claude Saltiel
AU  - Michel Martin
AU  - Laurence Vergne
AU  - Jocelyne Huet
AU  - Esteban Cvitkovic
PY  - 1991
JO  - European Journal of Cancer and Clinical Oncology
DO  - 10.1016/0277-5379(91)90089-v
UR  - https://doi.org/10.1016/0277-5379(91)90089-v
ER  - 

APA

Riggi, M., Ruffie, P., Voisin, S., Monnet, I., Cremoux, H. D., Saltiel, J. C., Martin, M., Vergne, L., Huet, J., & Cvitkovic, E. (1991). Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. European Journal of Cancer and Clinical Oncology. https://doi.org/10.1016/0277-5379(91)90089-v

Source records